(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 August 2022 (25.08.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/178180 A9

(51) International Patent Classification:
A61K 47/69 (2017.01) *A61P 25/00* (2006.01)
A61K 47/54 (2017.01) *A61P 29/00* (2006.01)
A61K 47/55 (2017.01) *A61P 35/00* (2006.01)
A61P 3/00 (2006.01)

(21) International Application Number:
PCT/US2022/016870

(22) International Filing Date:
17 February 2022 (17.02.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/150,523 17 February 2021 (17.02.2021) US

(71) Applicant: **CODIAK BIOSCIENCES, INC.** [US/US]; 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US).

(72) Inventors: **NOYES, Aaron**; c/o Codiak BioSciences, Inc., 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US). **ZHANG, Eric**; c/o Codiak BioSciences, Inc., 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US). **BROOM, Wendy**; c/o Codiak BioSciences, Inc., 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US). **WARREN, Chris**; c/o Codiak BioSciences, Inc., 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US). **ZHANG, Yaozhong**; c/o Codiak BioSciences, Inc., 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US). **ROSE, Erika**; c/o Codiak BioSciences, Inc., 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US).

(74) Agent: **KIM, Ji Eun** et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(54) Title: EXTRACELLULAR VESICLE LINKED TO A BIOLOGICALLY ACTIVE MOLECULE VIA AN OPTIMIZED LINKER AND AN ANCHORING MOIETY




FIG. 1

(57) Abstract: The present disclosure relates to extracellular vesicles (e.g., exosomes) comprising a biologically active molecule covalently linked to the extracellular vesicle via an optimized linker and an anchoring moiety, which may be useful as an agent for the prophylaxis or treatment of cancer or other diseases. Also provided herein are methods for producing the extracellular vesicles and methods for using the extracellular vesicles to treat diseases or disorders.

[Continued on next page]

WO 2022/178180 A9

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
22 September 2022 (22.09.2022)

(15) Information about Correction:
see Notice of 22 September 2022 (22.09.2022)